Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
about
Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisHIV-1 genetic variation and drug resistance development.Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis.Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infectionRilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA < 500,000 copies/mL.HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.
P2860
Q26851997-158C1C03-A046-495E-A868-166109597B2EQ28486262-DA18076B-50CF-4D16-AC75-F5A27C0007D6Q30354857-0C300037-C325-42BA-9317-C8832C2999CFQ33902540-DFEE8DD2-1268-44CC-BA98-C7C9E17CF374Q34457230-43701A0A-B98B-4A3C-8C1C-82991ED9D9EDQ38632038-7FF08141-66C6-44C7-AF15-A318F014F934Q40688534-701C5308-3D80-4D7D-8DCE-A6CAFBA73E2EQ41668874-CC62A0F5-04D9-4835-968B-905AFB414800Q46000779-F46E4F32-5415-4898-810F-1A6D7B5359D1Q47290558-54AA6DAF-500E-4CC6-BC58-24B18E305991Q55020251-899ABF40-DE0B-415B-B41C-54FD6A04646D
P2860
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combination of V106I and V179D ...... nevirapine but not etravirine.
@ast
Combination of V106I and V179D ...... nevirapine but not etravirine.
@en
type
label
Combination of V106I and V179D ...... nevirapine but not etravirine.
@ast
Combination of V106I and V179D ...... nevirapine but not etravirine.
@en
prefLabel
Combination of V106I and V179D ...... nevirapine but not etravirine.
@ast
Combination of V106I and V179D ...... nevirapine but not etravirine.
@en
P2093
P2860
P356
P1476
Combination of V106I and V179D ...... nevirapine but not etravirine.
@en
P2093
Atsuko Hachiya
Hironori Sato
Hirotaka Ode
Hiroyuki Gatanaga
Shinichi Oka
Tsunefusa Hayashida
P2860
P304
P356
10.1128/AAC.01480-09
P407
P577
2010-02-01T00:00:00Z